Novo Nordisk built modern obesity pharmacology. Liraglutide came first in 2009, with Saxenda following in 2014. Semaglutide split into three products — Ozempic for type-2 diabetes, Wegovy for obesity, and Rybelsus as the oral form. The 2025 and 2026 cadence has been about defending that position against Lilly's tirzepatide while moving the next generation forward.
The May 6 Q1 2026 print landed strong: net sales DKK 96.82B (+24% YoY), operating profit DKK 59.62B (+54%). Wegovy pill drove the upside with DKK 2.26B (~$354M) in Q1 — almost 2× analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative since the January 5 launch. CEO Mike Doustdar told CNBC on May 6 that Wegovy holds 65% of all new US GLP-1 prescriptions, calling the moment a 'turnaround situation.' NovoCare priced the 1.5 mg starter at $149/month and moved the 4 mg dose from $149 to $199 effective April 15. On May 1, Novo officially retired the Rybelsus US brand and re-launched the same molecule as Ozempic Pill at 1.5/4/9 mg with improved-absorption reformulation across 70,000+ pharmacies. Wegovy HD 7.2 mg launched April 7 with a STEP UP 21% mean weight loss anchor. Full-year guidance tightened to a 4–12% sales-and-operating-profit decline (from the prior 5–13%) — Jefferies pushed back that the lower-end guidance was not lifted enough to be a positive surprise.
The pipeline gets harder from here. CagriSema (cagrilintide + semaglutide) failed to match Zepbound in February's head-to-head readout (23% vs 25.5%), and the Q1 documents disclosed Novo has discontinued the single-chamber co-formulation device — the dual-chamber injectable system continues with the original FDA filing already submitted and a higher-dose Phase 3 trial slated for H2 2026. Petrelintide and amycretin-prodrug sit further back. The Indian semaglutide patent expired in March 2026 and licensed generics from Biocon and Dr. Reddy's followed within weeks.
International milestones continued through Q2 2026. Japan's MHLW granted Novo Nordisk a partial change approval on June 19, 2026 making Wegovy the first approved MASH treatment in Japan (without cirrhosis, moderate-to-advanced fibrosis), co-promoted with Sumitomo Pharma under the October 2025 co-promotion agreement and based on ESSENCE Phase 3 Part 1 data. France joined the UK and Switzerland with public-insurance reimbursement effective June 15, 2026 at 65% Sécurité Sociale coverage, and the UAE became the first ex-US Wegovy pill launch on June 3.
Seoul Economic Daily published Monday August 17, 2026 a market synthesis on the obesity drug runner-up field. Key runners-up positioning for 2027-2028 approval filings behind Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO): Structure Therapeutics (NASDAQ: GPCR) with aleniglipron (once-daily oral small-molecule GLP-1 receptor agonist) expected to initiate Phase 3 in H2 2026; Amgen (NASDAQ: AMGN) with MariTide (once-monthly injectable dual GIPR antagonist / GLP-1 agonist) now positioned as the sole obesity focus after the July 29 Q2 disclosure that Amgen halted AMG 513 Phase 1 development to concentrate resources on the MariTide MARITIME Phase 3 program; and Pfizer (NYSE: PFE) with danuglipron oral GLP-1 receptor agonist plus the Metsera acquisition pipeline. Amgen expects to apply for MariTide regulatory approval in late 2026 to early 2027. The Amgen MariTide Phase 3 program covers obesity (MARITIME-1) plus obesity and type 2 diabetes (MARITIME-2), with additional Phase 3 studies exploring cardiovascular disease, heart failure, kidney disease, and obstructive sleep apnea. The sorting of winners from losers based on Phase 3 results will begin in earnest starting next year as the field competes on efficacy, safety, delivery format, and price for market share behind Lilly's Zepbound-Mounjaro-Foundayo franchise and Novo's Wegovy-Ozempic franchise.
Novo Nordisk (NYSE: NVO) shares fell approximately 6% Thursday August 13, 2026 on broker downgrade citing continued franchise-gap pressure from Eli Lilly's tirzepatide franchise (Mounjaro + Zepbound) and the CagriSema head-to-head miss against tirzepatide. Specifics: CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg fixed-dose combination) reached 23.0% weight loss at 84 weeks versus tirzepatide 15 mg's 25.5% in the REDEFINE 4 head-to-head Phase 3 trial published in early August 2026. The August 4 H1 2026 earnings release raised full-year 2026 sales guidance to down 3% from a prior down 8% midpoint at constant exchange rates. The broader investor narrative continues to focus on Novo's ability to defend GLP-1 franchise economics against Eli Lilly's Q2 2026 $23 billion revenue blowout (+48% year-over-year), Foundayo (orforglipron) $98 million first commercial quarter, and retatrutide's 28.7% Phase 3 TRIUMPH-4 weight loss result at 68 weeks. Analyst attention now shifts to Novo's Wegovy 7.2 mg higher-dose FDA review, the amycretin oral amylin monotherapy Phase 1b program (roughly 22% weight loss at Week 36), and next-generation candidates in Novo's pipeline. Investors are also watching the CagriSema FDA decision expected late 2026 and whether the label expansion strategy can offset the competitive pressure.
Novo Nordisk released detailed data from the REDEFINE 4 head-to-head 84-week Phase 3 trial of CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg fixed-dose combination) versus tirzepatide 15 mg. Trial design: 809 randomized adults with obesity and one or more comorbidities with mean baseline body weight of 114.2 kg, both drugs administered once weekly subcutaneously over 84 weeks. Primary endpoint results: CagriSema 23.0% weight loss versus tirzepatide 25.5% (treatment-policy estimand); CagriSema 20.2% versus tirzepatide 23.6% (treatment-regimen estimand). The trial missed the primary non-inferiority endpoint on weight loss for CagriSema compared to tirzepatide at 84 weeks. CagriSema safety profile was generally well-tolerated. The trial result complicates the Novo commercial positioning of CagriSema as its tirzepatide-beating differentiated response, though the FDA decision on the CagriSema obesity indication remains expected late 2026 based on the REDEFINE 1 and REDEFINE 2 pivotal trials submitted December 18, 2025. The head-to-head result adds to the widening Lilly-Novo franchise gap: Lilly Q2 2026 Mounjaro + Zepbound reached $14.9 billion in the quarter, while Novo H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion).
The higher-dose Wegovy 7.2 mg (semaglutide 7.2 mg once weekly subcutaneous injection, up from the current 2.4 mg maximum approved dose) is currently under FDA review for the adult obesity indication. The submission is based on the Phase 3 STEP UP trial that documented approximately 19% weight loss at the 7.2 mg dose over 68 weeks, versus approximately 15% weight loss for the currently-approved 2.4 mg dose (based on STEP 1 registrational data). The higher-dose submission provides Novo Nordisk with a line-extension option to defend the Wegovy franchise economics against the Eli Lilly tirzepatide franchise (Zepbound and Mounjaro), which continues to outperform on weight loss (approximately 21% at the 15 mg weekly dose per SURMOUNT-1). The Wegovy 7.2 mg efficacy also lags the Lilly retatrutide triple-agonist Phase 3 TRIUMPH-4 data that documented 28.7% mean body weight reduction at the 12 mg dose (the highest weight-loss magnitude in any Phase 3 obesity trial to date). Novo Nordisk's line-extension strategy is under scrutiny following the CagriSema REDEFINE 4 head-to-head miss versus tirzepatide (23.0% vs 25.5% treatment-policy estimand at 84 weeks). FDA decision timing on Wegovy 7.2 mg has not been publicly disclosed.
Novo Nordisk's experimental CagriSema (cagrilintide plus semaglutide fixed-dose combination) reportedly failed to control blood sugar as effectively as Eli Lilly's tirzepatide (Mounjaro/Zepbound) in a head-to-head Phase 3 trial of patients with type 2 diabetes. CagriSema regulatory filing was submitted December 18, 2025 with an expected FDA decision in late 2026 for obesity indication; the type 2 diabetes head-to-head failure complicates the commercial narrative and label-expansion strategy. The trial outcome adds to the widening Lilly-Novo franchise gap documented across the Q2 2026 earnings week: Eli Lilly (NYSE: LLY) Q2 revenue reached $23 billion (+48% year-over-year) with Foundayo (orforglipron oral small-molecule GLP-1) delivering $98 million in its first fully operational commercial quarter and Mounjaro + Zepbound combined at $14.9 billion; Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency) with shares declining 5% on margin-compression concerns despite raised guidance. Investor narrative on Novo's ability to defend GLP-1 franchise economics continues to deteriorate as the amylin analog (cagrilintide) that Novo positioned as its differentiator against tirzepatide's dual GIP/GLP-1 mechanism failed to close the efficacy gap in the head-to-head setting.
Novo Nordisk (NYSE: NVO) shares fell approximately 5% across Tuesday and Wednesday August 4-5, 2026 following the H1 2026 earnings release. CEO Lars Fruergaard Jorgensen defended Wegovy pill economics on the earnings call, addressing analyst concerns about the compressed margin trajectory from the Most-Favored-Nation pricing deals announced with the Trump administration in November 2025 (which paired lower drug prices with expanded Medicare access and a three-year tariff grace period) and the Medicare GLP-1 Bridge Program launched July 1, 2026 (providing Wegovy, Zepbound KwikPen, and Foundayo at a capped $50/month copay for eligible Medicare Part D beneficiaries through December 31, 2027). Both programs reduce net realized prices per unit even as prescription volume climbs. Wegovy pill (oral semaglutide 25/50 mg for obesity) has reached more than 5 million cumulative US prescriptions since the Q1 2026 launch, one of the fastest oral obesity-drug uptake curves on record. Novo Nordisk H1 2026 sales reached 78.49 billion Danish kroner ($12.09 billion, +3% constant currency); the company raised full-year 2026 guidance from prior expectations to down 6% to flat at constant exchange rates. Analyst attention now focuses on 2027 pricing environment and Novo's ability to defend franchise economics as Eli Lilly's tirzepatide and orforglipron continue to widen the competitive gap.
The peptide-and-obesity Q2 2026 earnings week (Merck August 4, Pfizer August 4, Amgen August 4, Eli Lilly August 5, Novo Nordisk H1 August 4-5) delivered mixed signals across the pharma sector. Merck (NYSE: MRK) posted $16.61 billion Q2 revenue (+5% YoY, beat consensus by $250M), raised FY revenue guidance to $66.3-67.3 billion but cut adjusted EPS guidance to $2.66-2.76 due to a $5.7 billion Terns Pharmaceuticals acquisition charge; Keytruda reached $8.37 billion (+5%) and LIPFENDRA (enlicitide) launched at $315/month with $5 billion peak sales potential by 2034. Pfizer (NYSE: PFE) reported $15 billion revenue and $0.77 adjusted diluted EPS, raised FY revenue guidance midpoint to $60.5-62.5 billion, and CEO Bourla said the obesity program (danuglipron plus Metsera pipeline) is advancing with substantial momentum. Amgen (NASDAQ: AMGN) reported $10.05 billion Q2 revenue (+10% YoY), raised FY guidance to $38.2-39.4 billion, discontinued AMG 513 early-stage obesity candidate leaving MariTide as sole obesity focus. Eli Lilly (NYSE: LLY) delivered $23 billion Q2 revenue (+48% YoY blowout), raised FY guidance to $85-87 billion, Mounjaro reached $9.9 billion (+91%), Zepbound $4.9 billion US (+44%), and Foundayo generated $98 million in first fully operational commercial quarter. Novo Nordisk H1 reached 78.49 billion DKK ($12.09 billion, +3% CER) with Wegovy pill at 5 million+ prescriptions and raised guidance; NVO shares fell 5% on margin concerns. Alnylam (NASDAQ: ALNY) extended a 30% selloff (approximately $12 billion market cap lost) since the July 30 Q2 report on the Amvuttra TTR guidance cut plus eplontersen setback.
Novo Nordisk reported Q2 2026 earnings Tuesday August 4, 2026 with sales of 78.49 billion Danish kroner ($12.09 billion, +3% constant currency, +7% adjusted). Franchise performance: Wegovy injectable reached 19.484 billion DKK (+1% year-over-year); Wegovy pill (oral semaglutide 25/50 mg for obesity, launched Q1 2026) generated 3.218 billion DKK on more than 5 million cumulative prescriptions since launch; Ozempic (semaglutide for type 2 diabetes) grew 3% to 31.375 billion DKK. Novo Nordisk hiked its 2026 adjusted sales guidance to down 6% to flat at constant exchange rates, an improvement from the previous guidance that had reflected the substantially compressed pricing environment from the Trump administration Most-Favored-Nation deals and the July 1 Medicare GLP-1 Bridge Program launch. The Wegovy pill launch trajectory (5 million prescriptions in roughly six months) is one of the fastest oral obesity-drug uptake curves on record and effectively confirms the strength of the SNAC-enhanced oral peptide formulation strategy that Novo has pursued since the 2019 Rybelsus approval for type 2 diabetes. Novo shares tanked despite the raised outlook, reflecting concern about the tough Q2 2025 comparison and margin trajectory into 2027.
Eli Lilly (NYSE: LLY) reports Q2 2026 earnings Wednesday August 5, 2026 before market open with analyst consensus at $20.5 billion revenue and $7.74 EPS. Primary analyst focus numbers: Foundayo (orforglipron) weekly prescription volumes near 20,000 as the initial commercial ramp indicator following the April 2026 FDA approval as the first oral small-molecule non-peptide GLP-1 receptor agonist; Mounjaro (tirzepatide, type 2 diabetes indication) and Zepbound (tirzepatide, obesity indication) sales trajectory (Q1 2026 combined revenue $12.82 billion, approximately 65% of Lilly total revenue, driven by U.S. commercial volume plus international expansion with aggregate international Mounjaro market share now north of 50% per Lilly executive commentary at Goldman Sachs Healthcare Conference); full-year 2026 revenue guidance currently at $83-85 billion for potential revision; and the international pricing pressure headwind with management guiding low-to-mid-teens price erosion for FY26. Novo Nordisk reports H1 2026 results the same Wednesday August 5. Wegovy pill (oral semaglutide 25/50 mg for obesity) Q1 2026 sales of approximately $354 million provide the H1 baseline for the Novo pill franchise; injectable Wegovy Q1 2026 sales were $18.2 billion Danish kroner (+12% YoY).
Q2 2026 earnings from the peptide-and-obesity big three arrive next week. Merck (NYSE: MRK) reports Tuesday August 4 before market open with analyst consensus at $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025), reflecting post-Keytruda loss-of-exclusivity strategic repositioning and LIPFENDRA (enlicitide, oral macrocyclic peptide PCSK9 inhibitor approved July 16, 2026) launch costs. Eli Lilly (NYSE: LLY) reports Wednesday August 5 before market open with analyst consensus at $20.26 billion revenue and $6.71 EPS. Prediction markets put a 70% probability on another Lilly earnings beat, 96.4% odds Mounjaro (tirzepatide) clears $7.5 billion Q2, 87% odds Zepbound (tirzepatide) tops $4 billion Q2, and Foundayo (orforglipron, oral small-molecule GLP-1) weekly prescriptions near 20,000 as the primary analyst focus number after the April 2026 FDA approval. Novo Nordisk reports Wednesday August 5 H1 2026 results (Novo reports half-year rather than quarterly), with Wegovy pill (oral semaglutide 25/50 mg) Q1 2026 sales of approximately $354 million providing the H1 baseline. The three earnings prints together will frame second-half 2026 obesity market trajectory and the competitive positioning across incretin, macrocyclic peptide, and small-molecule oral GLP-1 franchises.
President Trump's Section 232 pharmaceutical tariffs took effect Friday July 31, 2026 for the 17 companies named in the initial tranche of the Section 232 national-security investigation. The Section 232 pathway allows the President to impose tariffs on imports that threaten national security; the pharmaceutical investigation was announced April 1, 2025 by the Commerce Department under the Trump administration and formally initiated April 30, 2026. Companies in the initial tranche face tariffs on active pharmaceutical ingredient (API) and finished-drug imports depending on manufacturing-location documentation; the broader pharmaceutical industry faces a September 29 deadline for additional tariff applicability. Peptide-and-obesity-relevant sponsors including Novo Nordisk (Wegovy/Ozempic semaglutide, primarily manufactured in Denmark), Eli Lilly (Zepbound/Mounjaro tirzepatide and Foundayo orforglipron, primarily manufactured in Ireland and Indiana), Merck (LIPFENDRA/enlicitide macrocyclic peptide PCSK9, manufacturing across US and Ireland), AstraZeneca (elecoglipron and biologics portfolio), Sanofi (Dupixent dupilumab), AbbVie (Skyrizi and Rinvoq), Roche, Bristol-Myers Squibb, Amgen, Pfizer, and Biogen all face potential 25% import duties depending on manufacturing-location documentation. President Trump also announced Tuesday July 21 that imported generic drugs would face zero tariffs for two years starting August 2028, providing a two-year runway before generic tariffs begin.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
Novo Nordisk announced Friday July 24, 2026 that it has filed for a temporary restraining order (TRO) and preliminary injunction in the US District Court for the District of New Jersey to immediately block Eli Lilly's national Zepbound (tirzepatide) and Mounjaro (tirzepatide) direct-to-consumer advertising campaigns. The escalation comes three business days after Novo's original complaint filed Tuesday July 21 alleging that Lilly's ads rely on outdated Wegovy (semaglutide) dose comparisons that do not account for the newer, higher-dose FDA-approved semaglutide options currently available. Through the TRO and preliminary injunction motions, Novo Nordisk seeks immediate court-ordered removal of the disputed Lilly campaigns pending a full merits ruling on the underlying deceptive-advertising claims. Novo also seeks a permanent injunction requiring Lilly to pull all misleading comparative advertising across platforms and to conduct a corrective advertising campaign. The GLP-1 ad war has moved from network TV pharmacy-facing PBM negotiation into full federal court litigation for the first time in the class's US commercialization history. Court hearing dates on the TRO/preliminary injunction have not yet been reported publicly.
Novo Nordisk (NYSE: NVO) filed a federal lawsuit Tuesday July 21, 2026 against Eli Lilly (NYSE: LLY) alleging that Lilly has run 'deceptive' advertising campaigns for its GLP-1 drugs Zepbound and Mounjaro (both tirzepatide), per STAT News reporting. The Novo complaint reportedly targets marketing claims that make Lilly's tirzepatide franchise appear more effective than the underlying clinical data support relative to Novo's Wegovy and Ozempic (both semaglutide). The lawsuit arrives against a competitive backdrop where Lilly has been extending its US commercial lead in the obesity market: Q1 2026 sales showed Mounjaro at $8.7 billion (up 125% year-over-year) and Zepbound at $4.2 billion (up 80%), while Novo Nordisk faced flat-to-declining semaglutide revenue after March 2026 price cuts, and Lilly overtook Novo in US GLP-1 market share. The SURMOUNT-5 head-to-head Phase 3 trial published earlier in 2026 showed superior efficacy for tirzepatide over semaglutide on weight loss endpoints; Novo's complaint appears to focus on how Lilly extrapolates the SURMOUNT-5 comparative data into consumer-facing advertising. The dispute frames the GLP-1 marketing battlefield ahead of Q2 earnings reports (Lilly August 5, Novo August 6).
STAT News published a major investigation Monday July 20, 2026 reporting that LifeMD, a US telehealth company promoted by Novo Nordisk as a partner for Wegovy and Ozempic access, has pushed clinicians to see more patients and dispense GLP-1 prescriptions more rapidly while providing what former workers describe as minimal screening and follow-up. Five former employees and two lawsuits filed by former top leaders allege that providers at LifeMD were pressed to review up to 25 patient cases per hour based only on the electronic intake forms patients themselves filled out, translating to approximately two minutes per case. Novo Nordisk currently lists LifeMD on its website as a partner that offers 'legitimate medicine sourcing and patient support' for people seeking GLP-1 drugs. LifeMD strenuously denies the allegations. The reporting extends the June-July concern set documented by the JAMA secret-shopper study (45 of 49 online sellers wrote semaglutide or tirzepatide prescriptions within a day with limited clinical oversight, July 7 digest coverage) and complements the peptide-telehealth-landscape reporting the site has tracked through 2026. The LifeMD story sits within the sprawling loosely-regulated GLP-1 telehealth industry that experts say has been boosted by Novo Nordisk and Eli Lilly as branded-drug demand expanded through 2025 and 2026.
Q2 2026 earnings season for the peptide-and-obesity big three opens next week. Merck reports Tuesday August 4 at 9:00 AM ET with the LIPFENDRA (enlicitide) FDA approval milestone (July 16) roughly one week old at report time; analyst focus areas include the pricing strategy at $10.50 per tablet ($315 per 30-day supply), the pharmacy-benefit distribution model, and initial payer coverage momentum. Eli Lilly reports Wednesday August 5 before market open; analyst focus areas include Foundayo (orforglipron) first-quarter-out US retail sales (Q1 sales were not yet in the books at the last report), Mounjaro and Zepbound growth versus the Wegovy pill franchise, and TRIUMPH-2 and TRIUMPH-3 readouts for retatrutide expected later in 2026. Novo Nordisk reports Thursday August 6; analyst focus areas include the Wegovy pill uptake beyond the 3 million-prescription milestone documented at ADA 2026 (June), the impact of Novo's price cuts in China and India, the Vivani implant partnership announced July 7, and the response to analyst concerns about the January 2027 Wegovy list price reset to $675 (a 50% cut from current levels). The three earnings prints together are expected to frame the second-half 2026 obesity market trajectory and the competitive positioning of the incretin, amylin, and macrocyclic peptide franchises against each other.
Analyst dispersion around Hims & Hers Health (NYSE: HIMS) widened this week following the FDA career-staff briefing documents released June 29-30 concluding all seven PCAC peptides have insufficient evidence for 503A bulks-list inclusion. The four fresh price targets span nearly two-to-one: Truist Securities reiterated a Hold rating with a $23 price target, citing near-term-performance strength tempered by uncertainty around peptide-compounding regulation. BofA Securities raised its price target to $36 from $25 while maintaining Neutral, noting the FDA update is negative for the company's peptide-optionality narrative but not the core weight-loss business. Barclays' Glen Santangelo raised to $39 from $29 while maintaining Overweight, crediting improvements from the renewed Novo Nordisk partnership. Canaccord's Maria Ripps raised to $40 from $32 while maintaining Buy, citing the company's transition from compounded to branded weight-loss drugs. The 74% spread from lowest to highest target reflects analyst disagreement about how much of the Hims growth story now runs through peptide optionality versus branded-GLP-1 rails.
Fierce Pharma's weekly Oral GLP-1 Tracker, which leverages IQVIA data and analyst notes, reports that Eli Lilly's Foundayo (orforglipron) reached 19,879 US prescriptions in its ninth week of retail launch compared with 159,000 for Novo Nordisk's Wegovy pill (oral semaglutide 25 mg) in its 22nd week. Foundayo received FDA approval April 1, 2026 and began retail shipments through LillyDirect on April 6; the Wegovy pill received FDA approval December 22, 2025 and launched in early January 2026. Adjusting for launch timing, Foundayo tracks numerically behind Wegovy pill at equivalent weeks, though Lilly executives noted on the Q1 earnings call that Foundayo's first-week pace ran ahead of the Zepbound injectable launch (2024). Spherix Global Insights analysis attributes Wegovy pill's uptake advantage to first-mover positioning and physician familiarity with the Wegovy brand name established through the injectable franchise. Foundayo's Q2 sell-in run rate implies roughly $146 million in Q2 revenue and $1.6 billion for full-year 2026 by analyst modeling.